---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-26-002338"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:10:39.669655+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q1 revenue $2.3M, net income $32,860

## Summary
- Revenue of approx. $2.3M, down ~$0.2M from prior year quarter.
- Net income of $32,860, an improvement of $24,324 compared to net loss in same quarter last year.
- CEO cites improved operational efficiency and disciplined cost management.
- Company focuses on sharpening service portfolio and concentrating on highest-value markets.

## SEC filing metadata
- accession: 0001654954-26-002338
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/0001654954-26-002338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-26-002338
- JSON: https://secwatch.observer/filing/0001654954-26-002338.json
- Plain text: https://secwatch.observer/filing/0001654954-26-002338.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported quarter ended January 31, 2026 results: revenue approximately $2.3 million, net income $32,860.
  - Period: quarter ended January 31, 2026
  - Revenue: approximately $2.3 million
  - Net income: $32,860
  - Result: reported results
  source text: biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/0001654954-26-002338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.